Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-12-15

FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (SpecGx LLC)

View source ↗

Summary

FDA approved a supplemental application for the generic fixed-dose combination of buprenorphine hydrochloride and naloxone hydrochloride dihydrate (SpecGx LLC) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine hydrochloride and naloxone hydrochloride dihydrate (buprenorphine hydrochloride and naloxone hydrochloride dihydrate)

Snippet

SUPPL AP for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE)